133 related articles for article (PubMed ID: 1037443)
1. A comparison of the dissolution and bioavailability characteristics of three spironolactone tablet formulations, including preliminary data on two spironolactone metabolites.
Tidd MJ; Collins WT; Chamberlain J
J Int Med Res; 1976; 4(2):86-95. PubMed ID: 1037443
[TBL] [Abstract][Full Text] [Related]
2. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing comparative bioavailability of spironolactone tablets.
Clarke JM; Ramsay LE; Shelton JR; Tidd MJ; Murray S; Palmer RF
J Pharm Sci; 1977 Oct; 66(10):1429-32. PubMed ID: 579186
[TBL] [Abstract][Full Text] [Related]
5. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo availability of spironolactone from oral dosage forms.
Chao AY; Sanvordeker DR; Zagarella J; Mattes K; Nicholova B; Karim A
J Pharm Sci; 1976 Nov; 65(11):1630-4. PubMed ID: 993995
[TBL] [Abstract][Full Text] [Related]
7. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
8. [Bioavailability studies of two spironolactone-preparations (author's transl)].
Vergin H; Nuss U; Schwarzländer F; Strobel K; Weigand W; Hitzenberger G
Arzneimittelforschung; 1981; 31(9):1498-503. PubMed ID: 7197963
[TBL] [Abstract][Full Text] [Related]
9. [Biological availability of spironolactone in two different galenic forms (author's transl)].
Rameis H; Hitzenberger G; Horwatitsch H
Dtsch Med Wochenschr; 1979 Jun; 104(24):881-3. PubMed ID: 446311
[TBL] [Abstract][Full Text] [Related]
10. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
11. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone.
McInnes GT; Asbury MJ; Ramsay LE; Shelton JR; Harrison IR
J Clin Pharmacol; 1982; 22(8-9):410-7. PubMed ID: 7130430
[TBL] [Abstract][Full Text] [Related]
12. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study of relative biovailability of several spironolactone formulations in a steady-state test (author's transl)].
Rosenthal J; Jaeger H; Specker M
Arzneimittelforschung; 1979; 29(9):1428-32. PubMed ID: 583254
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
Sandall JM; Millership JS; Collier PS; McElnay JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
[TBL] [Abstract][Full Text] [Related]
16. Application of a simple fluorometric method on absorption of canrenone.
Radó JP; Szende L; Takó J; Nagy O; Kozma C
Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
[TBL] [Abstract][Full Text] [Related]
18. The bioavailability of two new preparations of spironolactone tablets.
Nijkerk AJ; Vermeer JM; Imanse M; De Vos D
Pharm Weekbl Sci; 1983 Oct; 5(5):210-2. PubMed ID: 6646986
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous separation and rapid determination of spironolactone and its metabolite canrenone in different pharmaceutical formulations and urinary matrices by capillary zone electrophoresis.
Li L; Huang Y; Zhao W; Zhang G; Zhang H; Chen A
J Sep Sci; 2016 Jul; 39(14):2869-75. PubMed ID: 27257119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]